1
|
Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA. Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 2024:10.1038/s41591-024-02998-5. [PMID: 38649781 DOI: 10.1038/s41591-024-02998-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Affiliation(s)
- Isabella C Glitza Oliva
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Sherise D Ferguson
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Roland Bassett
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Alexandra P Foster
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ida John
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tarin D Hennegan
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michelle Rohlfs
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jessie Richard
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Masood Iqbal
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tina Dett
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Carol Lacey
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Natalie Jackson
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Theresa Rodgers
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Suzanne Phillips
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sheila Duncan
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Lauren Haydu
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ruitao Lin
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Rodabe N Amaria
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael K Wong
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Adi Diab
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Cassian Yee
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sapna P Patel
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jennifer L McQuade
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Grant M Fischer
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ian E McCutcheon
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Barbara J O'Brien
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sudhakar Tummala
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Matthew Debnam
- Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nandita Guha-Thakurta
- Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jennifer A Wargo
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Fernando C L Carapeto
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Courtney W Hudgens
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason T Huse
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael T Tetzlaff
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
| | - Elizabeth M Burton
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Hussein A Tawbi
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael A Davies
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
2
|
Simon L, De Taddeo M, Coeurvolan A, Colpaert M, Richard J, Devoisselle JM, Morille M, Marcotte N, Bégu S, Lapinte V. Various lipid anchors on amphiphilic polyoxazolines to reach efficient intracellular delivery. Int J Pharm 2023:123103. [PMID: 37277088 DOI: 10.1016/j.ijpharm.2023.123103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 05/30/2023] [Accepted: 06/01/2023] [Indexed: 06/07/2023]
Abstract
This work aimed at evaluating the potential of amphiphilic polyoxazolines bearing lipid chain called lipopolyoxazolines to reach efficient intracellular delivery. Four lipid chains: linear saturated, linear unsaturated and two branched one of various length were associated to poly(2-methyl-2-oxazoline) block. The evaluation of their physicochemical features and their impact on cell viability and internalization capacity indicated that the linear saturated gathered the highest cell internalization with a good cell viability. Its intracellular delivery capacity was compared to the PEG reference (DSPE-PEG) after being formulated in liposomes and loaded with fluorescent probe. Both POxylated and PEGylated liposomes showed similar characteristics regarding size distribution, drug loading and cell viability. However, their intracellular delivery was dramatically different, with an improved delivery by 30 folds for the POxylated ones. This significantly better performance highlighted the difficulty of PEGylated liposomes to enter the cells by endocytosis, contrary to POxylated liposomes. This study promotes the value of lipopoly(oxazoline) as a lipopoly(ethylene glycol) alternative for effective intracellular delivery and holds great promises for development of nanoformulations for intravenous administration.
Collapse
Affiliation(s)
- L Simon
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - M De Taddeo
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - A Coeurvolan
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - M Colpaert
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - J Richard
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | | | - M Morille
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - N Marcotte
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - S Bégu
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - V Lapinte
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France.
| |
Collapse
|
3
|
Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 2023; 29:898-905. [PMID: 36997799 PMCID: PMC10115650 DOI: 10.1038/s41591-022-02170-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 12/02/2022] [Indexed: 04/01/2023]
Abstract
There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in patients with melanoma and LMD. The primary endpoints are determination of safety and the recommended IT nivolumab dose. The secondary endpoint is overall survival (OS). Patients are treated with IT nivolumab alone in cycle 1 and IV nivolumab is included in subsequent cycles. We treated 25 patients with metastatic melanoma using 5, 10, 20 and 50 mg of IT nivolumab. There were no dose-limiting toxicities at any dose level. The recommended IT dose of nivolumab is 50 mg (with IV nivolumab 240 mg) every 2 weeks. Median OS was 4.9 months, with 44% and 26% OS rates at 26 and 52 weeks, respectively. These initial results suggest that concurrent IT and IV nivolumab is safe and feasible with potential efficacy in patients with melanoma LMD, including in patients who had previously received anti-PD1 therapy. Accrual to the study continues, including in patients with lung cancer. ClinicalTrials.gov registration: NCT03025256 .
Collapse
Affiliation(s)
- Isabella C Glitza Oliva
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Sherise D Ferguson
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Roland Bassett
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Alexandra P Foster
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ida John
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tarin D Hennegan
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michelle Rohlfs
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jessie Richard
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Masood Iqbal
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tina Dett
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Carol Lacey
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Natalie Jackson
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Theresa Rodgers
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Suzanne Phillips
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sheila Duncan
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Lauren Haydu
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ruitao Lin
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Rodabe N Amaria
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael K Wong
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Adi Diab
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Cassian Yee
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sapna P Patel
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jennifer L McQuade
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Grant M Fischer
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ian E McCutcheon
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Barbara J O'Brien
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sudhakar Tummala
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Matthew Debnam
- Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nandita Guha-Thakurta
- Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jennifer A Wargo
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Fernando C L Carapeto
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Courtney W Hudgens
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason T Huse
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael T Tetzlaff
- Department of Pathology, The University of California San Francisco, San Francisco, CA, USA
| | - Elizabeth M Burton
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Hussein A Tawbi
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michael A Davies
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
4
|
Viox E, Richard J, Clark N, Grandea A, Hammad I, Janaka S, Crosno K, Capuano S, Pagliuzza A, Gaudette F, Bourassa C, Fritschi C, III AS, Chomont N, Sodroski J, Finzi A, Evans D, Paiardini M. PP 8.13 – 00191 Investigating the Impact of CD4 mimetic BNM-III-170 on SHIV-infected Rhesus Macaques. J Virus Erad 2022. [DOI: 10.1016/j.jve.2022.100293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
5
|
John I, Foster AP, Haymaker CL, Bassett RL, Lee JJ, Rohlfs ML, Richard J, Iqbal M, McCutcheon IE, Ferguson SD, Heimberger AB, Saberian CM, O'Brien BJ, Tummala S, Guha- Thakurta N, Debnam M, Tawbi HAH, Burton EM, Davies MA, Glitza IC. Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.9519] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9519 Background: MM pts with LMD have a dismal prognosis, with median overall survival (OS) < 3 months, no approved therapies and extremely limited clinical trial options. We previously reported initial safety findings from an open label, single arm, single center phase I/IB trial (NCT03025256), in which IT and IV N were well tolerated, without any CNS-specific or unexpected toxicity. Here we report an update on safety and maximum tolerated dose (MTD) for all patients enrolled, and efficacy for the completed dose cohorts. Methods: MM patients aged >18 with evidence of LMD by MRI and/or CSF cytology, ECOG PS ≤2 were treated with IT and IV N. Dexamethasone ≤4mg/daily and concurrent BRAF/MEK inhibitor(i) treatment was allowed. For cycle 1, IT N was administered via intraventricular reservoir on day (D)1. For subsequent cycles (every 14 days), pts received IT N on D1, followed by IV N 240 mg on D2. IT N doses evaluated were 5, 10, 20 mg and 50 mg. Blood and CSF were collected at multiple time points for translational research. The primary objectives of this first-in-human study were to determine the safety and MTD of IT N given with IV N in MM pts with LMD. Bayesian mTPI methodology was used to define the MTD. Results: To date, 23 pts have been treated: two at 5, three at 10, fourteen at 20 mg and four at 50 mg IT N. Median age at LMD diagnosis was 42 (28-73); 12 pts are male. All pts had radiographic evidence of LMD and neurological symptoms; 14 pts had positive CSF cytology at baseline. 21 pts received prior therapies for their metastatic melanoma: anti-PD1 (n = 19), BRAFi/MEKi (n = 14), chemo (n = 2), IT IL2 (n = 4) other (n = 2). 19 pts had prior XRT, including whole brain RT (n = 7). Two pts were treatment-naïve. The median number of IT N doses was five (1- 66). The combination regimen was well tolerated by all evaluable pts (n=23), with only five pts (22%) experiencing gr 3 AEs, and no reported gr 4 or 5 toxicities. Nausea (30%), diarrhea (26%), and rash (22%) were the most common AEs. Eight pts (23%) experienced AEs after IT N administration, all gr 1. Initial efficacy analysis included only pts (n=19) treated with first three dose levels (5-20mg). Median follow-up for these pts is 4.5 months (mos) (1.1, 31.5 mos) and median OS is 63 % at 3 mos, 42 % at 6 mos and 30% at 12 mos. Conclusions: The trial demonstrates the feasibility and safety of IT administration of modern immunotherapy for MM pts with LMD. No unexpected systemic or neurological toxicity was observed with 20mg IT N. 2 additional patients are required to complete the 50mg IT N cohort. OS rates at 6 and 12 mos are encouraging and support further evaluation of IT administration of immunotherapy agents for pts with MM and LMD. Final presentation will include results of LMD for all dose cohorts, composite response assessment and comparative analysis of longitudinal CSF samples to assess immunologic effects. Clinical trial information: NCT03025256.
Collapse
Affiliation(s)
- Ida John
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | - J. Jack Lee
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Jessie Richard
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Masood Iqbal
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Amy B. Heimberger
- The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX
| | | | - Barbara Jane O'Brien
- The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX
| | | | | | - Matthew Debnam
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | |
Collapse
|
6
|
Cobb J, Craig W, Richard J, Snow E, Turcotte H, Warters R, Quaye A. Low-dose ketamine infusion for post-cesarean delivery analgesia in patients with opioid use disorder. Int J Obstet Anesth 2021; 47:103170. [PMID: 34090769 DOI: 10.1016/j.ijoa.2021.103170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 04/09/2021] [Accepted: 04/24/2021] [Indexed: 10/21/2022]
Affiliation(s)
- J Cobb
- Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - W Craig
- Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USA
| | - J Richard
- Department of Anesthesiology & Perioperative Medicine, Maine Medical Center, Portland, ME, USA
| | - E Snow
- Family Birth Center, Maine Medical Center, Portland, ME, USA
| | - H Turcotte
- Department of Anesthesiology & Perioperative Medicine, Maine Medical Center, Portland, ME, USA
| | - R Warters
- Department of Anesthesiology & Perioperative Medicine, Maine Medical Center, Portland, ME, USA; Spectrum Healthcare Partners, South Portland, ME, USA
| | - A Quaye
- Department of Anesthesiology & Perioperative Medicine, Maine Medical Center, Portland, ME, USA; Spectrum Healthcare Partners, South Portland, ME, USA
| |
Collapse
|
7
|
Calas L, Ruello M, Hassani Y, Richard J, Gabet A, Olié V, Grave C. Hypertension prevalence, awareness, treatment and control in 2019 in the adult population of Mayotte. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2020.10.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Glitza IC, Phillips S, Brown C, Haymaker CL, Bassett RL, Lee JJ, Rohlfs ML, Richard J, Iqbal M, John I, McCutcheon IE, Ferguson SD, Heimberger AB, O'Brien BJ, Tummala S, Guha- Thakurta N, Debnam M, Burton EM, Tawbi HAH, Davies MA. Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.10008] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10008 Background: MM pts with LMD have a dismal prognosis, with a median overall survival (OS) < 3 months and no approved therapies. IT administration of interleukin-2 (IL2) achieves survival in ~15% of MM LMD pts, but at cost of severe toxicities. Given the favorable clinical activity and safety of systemic anti-PD1, we hypothesized that IT N administration is safe and can achieve clinical benefit in pts with LMD. Methods: The primary objectives of this first-in-human study (NCT03025256) were to determine the safety and the maximum tolerated dose (MTD) of IT N given with IV N in MM pts with LMD. Eligible pts had MM, ECOG PS < / = 2, and evidence of LMD by MRI and/or CSF cytology. Dexamethasone < / = 4mg/daily was allowed. For cycle 1, IT N is administered via intraventricular reservoir on day (D) 1; Blood and CSF is collected at multiple time points for translational research. For subsequent cycles (every 14 days), pts receive IT N on D1, followed by IV N 240 mg on D2. IT N doses evaluated were 5, 10, and 20 mg. Bayesian mTPI methodology was used to define the MTD. The study was recently amended to allow for concurrent BRAF/MEK inhibitor(i) treatment. Results: To date, 15 pts have been treated: two at 5, three at 10, and 10 at 20 mg IT N. Median age at LMD diagnosis was 41.8 (30.9-73.2) years; 6 pts are male. All pts had radiographic evidence of LMD and neurological symptoms; 8 pts had positive CSF cytology. 12 pts received prior therapies for their MM: anti-PD1 (n = 11), BRAFi/MEKi (n = 9), chemo (n = 2), IT IL2 (n = 4) other (n = 2). 11 pts had prior XRT, including whole brain RT (n = 7). 1 pt was treatment-naïve. The median numbers of IT N doses was 4 (1-42). No grade (Gr) 4-5 AEs were attributed to IT N or IV N; only 4 events (Gr 1, n = 2; Gr2, n = 2) were possibly related to the IT N. With a median follow-up of 18.7 weeks (1-83.3 wks), the median OS is 46.1 weeks (0.1-83.3). Clinical response data, translational research endpoints, including changes in CSF cytokines and cfDNA, will be reported. Conclusions: The trial demonstrates the feasibility of prospective clinical trials in MM patients with LMD. The combination of IT/ IV N was safe and well-tolerated, with no unexpected systemic or neurological toxicity. Final presentation will include results of LMD composite response assessment, comparative analysis of longitudinal CSF/blood samples to assess immunologic effects. Finally, the interim OS of the patients is encouraging, and supports further evaluation of IT administration of immunotherapy agents for pts with MM and LMD. Clinical trial information: NCT03025256.
Collapse
Affiliation(s)
| | | | - Courtney Brown
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - J. Jack Lee
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Jessie Richard
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Masood Iqbal
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Ida John
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Amy B. Heimberger
- The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX
| | - Barbara Jane O'Brien
- The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX
| | | | | | - Matthew Debnam
- University Of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | |
Collapse
|
9
|
Wisotzki L, Bacon R, Brinchmann J, Cantalupo S, Richter P, Schaye J, Schmidt KB, Urrutia T, Weilbacher PM, Akhlaghi M, Bouché N, Contini T, Guiderdoni B, Herenz EC, Inami H, Kerutt J, Leclercq F, Marino RA, Maseda M, Monreal-Ibero A, Nanayakkara T, Richard J, Saust R, Steinmetz M, Wendt M. Author Correction: Nearly all the sky is covered by Lyman-α emission around high-redshift galaxies. Nature 2018; 563:E31. [PMID: 30377312 DOI: 10.1038/s41586-018-0664-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Change history: In this Letter, author M. Akhlaghi should be associated with affiliation (2) rather than (3). This error has been corrected online.
Collapse
Affiliation(s)
- L Wisotzki
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany.
| | - R Bacon
- Université Lyon, Université Lyon 1, ENS de Lyon, CNRS, Centre de Recherche Astrophysique de Lyon, Saint-Genis-Laval, France
| | - J Brinchmann
- Leiden Observatory, Leiden University, Leiden, The Netherlands.,Instituto de Astrofísica e Ciências do Espaço, Universidade do Porto, CAUP, Porto, Portugal
| | - S Cantalupo
- Department of Physics, ETH Zürich, Zürich, Switzerland
| | - P Richter
- Institut für Physik und Astronomie, Universität Potsdam, Potsdam, Germany
| | - J Schaye
- Leiden Observatory, Leiden University, Leiden, The Netherlands
| | - K B Schmidt
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany
| | - T Urrutia
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany
| | - P M Weilbacher
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany
| | - M Akhlaghi
- Université Lyon, Université Lyon 1, ENS de Lyon, CNRS, Centre de Recherche Astrophysique de Lyon, Saint-Genis-Laval, France
| | - N Bouché
- Institut de Recherche en Astrophysique et Planétologie (IRAP), Université de Toulouse, CNRS, Toulouse, France
| | - T Contini
- Institut de Recherche en Astrophysique et Planétologie (IRAP), Université de Toulouse, CNRS, Toulouse, France
| | - B Guiderdoni
- Université Lyon, Université Lyon 1, ENS de Lyon, CNRS, Centre de Recherche Astrophysique de Lyon, Saint-Genis-Laval, France
| | - E C Herenz
- Department of Astronomy, Stockholm University, AlbaNova University Centre, Stockholm, Sweden
| | - H Inami
- Université Lyon, Université Lyon 1, ENS de Lyon, CNRS, Centre de Recherche Astrophysique de Lyon, Saint-Genis-Laval, France
| | - J Kerutt
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany
| | - F Leclercq
- Université Lyon, Université Lyon 1, ENS de Lyon, CNRS, Centre de Recherche Astrophysique de Lyon, Saint-Genis-Laval, France
| | - R A Marino
- Department of Physics, ETH Zürich, Zürich, Switzerland
| | - M Maseda
- Leiden Observatory, Leiden University, Leiden, The Netherlands
| | - A Monreal-Ibero
- Instituto de Astrofísica de Canarias (IAC), La Laguna, Tenerife, Spain.,Universidad de La Laguna, Departamento Astrofísica, La Laguna, Tenerife, Spain
| | - T Nanayakkara
- Leiden Observatory, Leiden University, Leiden, The Netherlands
| | - J Richard
- Université Lyon, Université Lyon 1, ENS de Lyon, CNRS, Centre de Recherche Astrophysique de Lyon, Saint-Genis-Laval, France
| | - R Saust
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany
| | - M Steinmetz
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany
| | - M Wendt
- Leibniz-Institut für Astrophysik Potsdam (AIP), Potsdam, Germany.,Institut für Physik und Astronomie, Universität Potsdam, Potsdam, Germany
| |
Collapse
|
10
|
Glitza I, Rohlfs M, Iqbal M, Richard J, Burton E, Duncan S, Brown C, Anderson J, Hwu P, Hwu WJ, Wong M, Yee C, Patel S, Woodman S, Amaria R, Diab A, Tawbi H, Davies M. A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Collins TA, Hawkins RO, Flowers EM, Kalra HD, Richard J, Haas LE. Behavior Bingo: The effects of a culturally relevant group contingency intervention for students with EBD. Psychol Schs 2017. [DOI: 10.1002/pits.22091] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
12
|
Tan S, David J, Lalonde L, El Khoury M, Labelle M, Younan R, Patocskai E, Richard J, Trop I. Breast magnetic resonance imaging: are those who need it getting it? Curr Oncol 2017; 24:e205-e213. [PMID: 28680288 PMCID: PMC5486393 DOI: 10.3747/co.24.3441] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Indications for breast magnetic resonance imaging (mri), a very sensitive but less-specific tool for breast investigation, remain controversial, and accessibility is limited. The purposes of our study were to determine the proportion of breast mri exams performed for various clinical indications, to assess the wait times for breast mri, and to create a list of evidence-based indications for breast mri. METHODS The indications for breast mri exams performed in September 2013 at our academic centre were audited. A multidisciplinary meeting held in May 2014 established a list of evidence-based indications for breast mri, after which, in September 2014 and 2015, breast mri exams were re-audited for clinical indications, and pending requests were calculated. RESULTS In September 2013, surveillance of women with a prior diagnosis of breast cancer represented 21% of breast mri exams (24 of 113), with preoperative staging representing 18% of exams (20 of 113) and high-risk screening representing 12% (13 of 113). Of pending mri requests, 230 were within the recommended delay period, and 457 exceeded the recommended delay. After elaboration of evidence-based guidelines, repeat audits in September 2014 and September 2015 showed that mri performed for women with a prior breast cancer diagnosis represented 23% (33 of 141) and 7% (10 of 143) of exams respectively, with preoperative staging having declined to 9% (13 of 141) and 11% (16 of 143) of exams, and high-risk screening having increased to 36% (51 of 141) and 46% (66 of 143) of exams. Overall, wait times were improved for all breast mri indications. CONCLUSIONS Through multidisciplinary discussion, we actualized a list of breast mri indications, prioritized requests more adequately, and improved wait times.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - J. Richard
- Department of General Medicine, l’Université de Montréal, Montreal, QC
| | | |
Collapse
|
13
|
Richard J, Maitre A, Hervé C, Marques M, Bonneterre V, Barbeau D, Persoons R. Surveillance biologique de l’exposition professionnelle au styrène : déterminants de l’exposition et recommandations de prévention. ARCH MAL PROF ENVIRO 2017. [DOI: 10.1016/j.admp.2017.01.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Vandevyver M, Barraud A, Lesieur P, Richard J, Ruaudel-Teixier A. Couches de Langmuir-Blodgett conductrices obtenues à partir d'un sel complexe de TCNQ. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1986830599] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
15
|
Vandevyver M, Richard J, Barraud A, Veber M, Jallabert C, Strzelecka H. Langmuir-blodgett films of liquid-crystalline heteroaromatic cations associated with diamagnetic (BF4-, CIO4-) or paramagnetic (TCNQ[math]) anions. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1988850385] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
16
|
|
17
|
Gagnon J, Lévesque E, Borduas F, Chiquette J, Diorio C, Duchesne N, Dumais M, Eloy L, Foulkes W, Gervais N, Lalonde L, L'Espérance B, Meterissian S, Provencher L, Richard J, Savard C, Trop I, Wong N, Knoppers BM, Simard J. Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies. ACTA ACUST UNITED AC 2016; 23:e615-e625. [PMID: 28050152 DOI: 10.3747/co.23.2961] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
In recent years, risk stratification has sparked interest as an innovative approach to disease screening and prevention. The approach effectively personalizes individual risk, opening the way to screening and prevention interventions that are adapted to subpopulations. The international perspective project, which is developing risk stratification for breast cancer, aims to support the integration of its screening approach into clinical practice through comprehensive tool-building. Policies and guidelines for risk stratification-unlike those for population screening programs, which are currently well regulated-are still under development. Indeed, the development of guidelines for risk stratification reflects the translational aspects of perspective. Here, we describe the risk stratification process that was devised in the context of perspective, and we then explain the consensus-based method used to develop recommendations for breast cancer screening and prevention in a risk-stratification approach. Lastly, we discuss how the recommendations might affect current screening policies.
Collapse
Affiliation(s)
- J Gagnon
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - E Lévesque
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | | | - F Borduas
- Quebec City, QC: Public Health Branch, Capitale-Nationale (Borduas); Centre hospitalier universitaire ( chu ) de Québec-Université Laval (Chiquette, Duchesne, Provencher); Centre de coordination des services régionaux, Capitale-Nationale (Chiquette); Quebec Breast Cancer Screening Program (Chiquette, Eloy); chu de Québec-Université Laval Research Center and Department of Social and Preventive Medicine, Université Laval (Diorio); Cancer Branch, Ministry of Health and Social Services (Eloy); Deschênes-Fabia Breast Diseases Center (Provencher); chu de Québec-Université Laval (Duchesne); Canada Research Chair in Oncogenetics, chu de Québec-Université Laval Research Centre, and Department of Molecular Medicine, Université Laval (Simard)
| | - J Chiquette
- Quebec City, QC: Public Health Branch, Capitale-Nationale (Borduas); Centre hospitalier universitaire ( chu ) de Québec-Université Laval (Chiquette, Duchesne, Provencher); Centre de coordination des services régionaux, Capitale-Nationale (Chiquette); Quebec Breast Cancer Screening Program (Chiquette, Eloy); chu de Québec-Université Laval Research Center and Department of Social and Preventive Medicine, Université Laval (Diorio); Cancer Branch, Ministry of Health and Social Services (Eloy); Deschênes-Fabia Breast Diseases Center (Provencher); chu de Québec-Université Laval (Duchesne); Canada Research Chair in Oncogenetics, chu de Québec-Université Laval Research Centre, and Department of Molecular Medicine, Université Laval (Simard)
| | - C Diorio
- Quebec City, QC: Public Health Branch, Capitale-Nationale (Borduas); Centre hospitalier universitaire ( chu ) de Québec-Université Laval (Chiquette, Duchesne, Provencher); Centre de coordination des services régionaux, Capitale-Nationale (Chiquette); Quebec Breast Cancer Screening Program (Chiquette, Eloy); chu de Québec-Université Laval Research Center and Department of Social and Preventive Medicine, Université Laval (Diorio); Cancer Branch, Ministry of Health and Social Services (Eloy); Deschênes-Fabia Breast Diseases Center (Provencher); chu de Québec-Université Laval (Duchesne); Canada Research Chair in Oncogenetics, chu de Québec-Université Laval Research Centre, and Department of Molecular Medicine, Université Laval (Simard)
| | - N Duchesne
- Quebec City, QC: Public Health Branch, Capitale-Nationale (Borduas); Centre hospitalier universitaire ( chu ) de Québec-Université Laval (Chiquette, Duchesne, Provencher); Centre de coordination des services régionaux, Capitale-Nationale (Chiquette); Quebec Breast Cancer Screening Program (Chiquette, Eloy); chu de Québec-Université Laval Research Center and Department of Social and Preventive Medicine, Université Laval (Diorio); Cancer Branch, Ministry of Health and Social Services (Eloy); Deschênes-Fabia Breast Diseases Center (Provencher); chu de Québec-Université Laval (Duchesne); Canada Research Chair in Oncogenetics, chu de Québec-Université Laval Research Centre, and Department of Molecular Medicine, Université Laval (Simard)
| | - M Dumais
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - L Eloy
- Quebec City, QC: Public Health Branch, Capitale-Nationale (Borduas); Centre hospitalier universitaire (chu) de Québec-Université Laval (Chiquette, Duchesne, Provencher); Centre de coordination des services régionaux, Capitale-Nationale (Chiquette); Quebec Breast Cancer Screening Program (Chiquette, Eloy); chu de Québec-Université Laval Research Center and Department of Social and Preventive Medicine, Université Laval (Diorio); Cancer Branch, Ministry of Health and Social Services (Eloy); Deschênes-Fabia Breast Diseases Center (Provencher); chu de Québec-Université Laval (Duchesne); Canada Research Chair in Oncogenetics, chu de Québec-Université Laval Research Centre, and Department of Molecular Medicine, Université Laval (Simard);; Joliette, QC: Centre hospitalier régional de Lanaudière (Eloy)
| | - W Foulkes
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - N Gervais
- Rivière-du-Loup, QC: Centre hospitalier du Grand-Portage (Gervais)
| | - L Lalonde
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - B L'Espérance
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - S Meterissian
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - L Provencher
- Quebec City, QC: Public Health Branch, Capitale-Nationale (Borduas); Centre hospitalier universitaire ( chu ) de Québec-Université Laval (Chiquette, Duchesne, Provencher); Centre de coordination des services régionaux, Capitale-Nationale (Chiquette); Quebec Breast Cancer Screening Program (Chiquette, Eloy); chu de Québec-Université Laval Research Center and Department of Social and Preventive Medicine, Université Laval (Diorio); Cancer Branch, Ministry of Health and Social Services (Eloy); Deschênes-Fabia Breast Diseases Center (Provencher); chu de Québec-Université Laval (Duchesne); Canada Research Chair in Oncogenetics, chu de Québec-Université Laval Research Centre, and Department of Molecular Medicine, Université Laval (Simard)
| | - J Richard
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - C Savard
- St-Raymond, QC: Centre de santé et de services sociaux de Portneuf (Savard)
| | - I Trop
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - N Wong
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - B M Knoppers
- Montreal, QC: Centre of Genomics and Policy, Department of Human Genetics, McGill University (Gagnon, Lévesque, Knoppers); Quebec Breast Cancer Foundation [Dumais (observing member)]; Sir Mortimer B. Davis Jewish General Hospital and McGill University Health Centre (Foulkes); Breast Imaging Centre, Centre hospitalier de l'Université de Montréal (Lalonde, Trop); Hôpital du Sacré-Coeur de Montréal and Groupe d'Étude en Oncologie du Québec (L'Espérance); Royal Victoria Hospital and Cedars Breast Clinic of the McGill University Health Centre (Meterissian); Centre Intégré en traitement, recherche et enseignement en Cancer du Sein, Centre hospitalier de l'Université de Montréal (Richard); Sir Mortimer B. Davis Jewish General Hospital and McGill University (Wong)
| | - J Simard
- Quebec City, QC: Public Health Branch, Capitale-Nationale (Borduas); Centre hospitalier universitaire ( chu ) de Québec-Université Laval (Chiquette, Duchesne, Provencher); Centre de coordination des services régionaux, Capitale-Nationale (Chiquette); Quebec Breast Cancer Screening Program (Chiquette, Eloy); chu de Québec-Université Laval Research Center and Department of Social and Preventive Medicine, Université Laval (Diorio); Cancer Branch, Ministry of Health and Social Services (Eloy); Deschênes-Fabia Breast Diseases Center (Provencher); chu de Québec-Université Laval (Duchesne); Canada Research Chair in Oncogenetics, chu de Québec-Université Laval Research Centre, and Department of Molecular Medicine, Université Laval (Simard)
| |
Collapse
|
18
|
Arumugam S, Joseph P, Ponnaiya J, Richard J, Das M, Chaitanya VS, Ebenezer M. Evaluation of New Antibacterial Drugs and their Combinations in a Murine Model to Identify Short Duration Alternative Chemotherapy for Leprosy. Indian J Lepr 2016; 88:159-176. [PMID: 30207441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The objective of the research is to test the efficacy of new drugs and drug combinations in mice infected with Mycobacterium leprae (M. leprae) as alternative to current WHO MDT. Individual drugs tested were Rifampicin (RMP), Rifapentine (RPT) and Moxifloxacin (MOXI). Drug combinations were RMP, Clarithromycin (CLARI), Minocycline (MINO) and RMP, MINO and Ofloxacin (OFLO). RPT drug combinations were RPT, CLARI, MINO and RPT, OFLO, MINO. Both the drugs and drug combinations were used as daily regimen and intermittent regimen. WHO MB MDT served as a positive control. Mice pre-inoculated with M. leprae were allotted to daily and intermittent groups and administered selected drugs and drug combinations. At the end of 12 months post sub-inoculation, mice were sacrificed and the proportion % of viable bacilli were counted using Spearman and Karber method. It was noted that RMP, RPT and Moxifloxacin indicated a range of 89.99% to 99.99% bactericidal effect when used in daily or intermittent doses in both normal and TR mice. Drug combinations showed bactericidal effect comparable to that of WHO MDT. From the study it was concluded that if the present duration of MDT has to be shortened then daily dose regimen with RMP/MINO/OFLO or RPT/CLARI/MINO are recommended for a clinical trial.
Collapse
|
19
|
O'Brien PJ, Smith DEC, Knechtel TJ, Marchak MA, Pruimboom-Brees I, Brees DJ, Spratt DP, Archer FJ, Butler P, Potter AN, Provost JP, Richard J, Snyder PA, Reagan WJ. Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim 2016; 40:153-71. [PMID: 16600075 DOI: 10.1258/002367706776319042] [Citation(s) in RCA: 208] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
This study directly demonstrates that cardiac troponin I (cTnI) is a sensitive, specific, and persistent biomarker in laboratory animals. Histopathological and pathophysiological cardiac changes in dogs, rats and mice correlated with increased serum cTnI with various cardiac inotropic agents, and cardiotoxic drugs and with cardiac arrhythmias, tachycardia, cardiac effusion with dyspnoea, and ageing. A comparison of six immunoassays for cTnI and cardiac troponin T (cTnT) to detect and monitor cardiac injury in a rodent model indicated that enzyme-linked immunosorbent (Life Diagnostics Inc and TriChem Resources Inc, West Chester, Philadelphia, USA) and Immulite (Diagnostic Products Corporation, Llanberis, UK) assays had low sensitivity and less than 1% of the dynamic range of Centaur (Bayer Healthcare Diagnostics, Newbury, UK) cTnI and Elecsys (Roche Diagnostics, Basel, Switzerland) and M8 (Bioveris Europe, Whitney, UK) cTnT assays. In dogs, however, the Immulite assay was effective and correlated with the Centaur. Serum concentrations were highly correlated but 10-fold lower for cTnT compared with cTnI with cardiac injury. Centaur assay also detected cTnI in myocardium from marmosets, swine, cattle, and guineapigs, indicating it to be candidate cardiac biomarker for these species as well. Purified rat cTnI was 50% more reactive than purified human cTnI in the Centaur assay. In the rat, an age- and gender-dependent variation in serum cTnI was found. Male rats aged six and eight months had a 10-fold greater serum cTnI than age-matched females and three-month-old rats. These increases correlated with minimal histopathological change. Isoproterenol-induced serum cTnI increased up to 760-fold the minimal detectable concentration of 0.07 μg/L, within 4–6 h and decreased with a half-life of 6 h, with an expected return to baseline of 60 h. Severity of histopathological change correlated with serum cTnI during the ongoing injury.
Collapse
Affiliation(s)
- P J O'Brien
- Safety Sciences Europe, Sandwich, Kent CT1 3NJ, UK. Peter.O'
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Garver KA, Marty GD, Cockburn SN, Richard J, Hawley LM, Müller A, Thompson RL, Purcell MK, Saksida S. Piscine reovirus, but not Jaundice Syndrome, was transmissible to Chinook Salmon, Oncorhynchus tshawytscha (Walbaum), Sockeye Salmon, Oncorhynchus nerka (Walbaum), and Atlantic Salmon, Salmo salar L. J Fish Dis 2016; 39:117-28. [PMID: 25630226 DOI: 10.1111/jfd.12329] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 10/27/2014] [Accepted: 11/02/2014] [Indexed: 05/12/2023]
Abstract
A Jaundice Syndrome occurs sporadically among sea-pen-farmed Chinook Salmon in British Columbia, the westernmost province of Canada. Affected salmon are easily identified by a distinctive yellow discolouration of the abdominal and periorbital regions. Through traditional diagnostics, no bacterial or viral agents were cultured from tissues of jaundiced Chinook Salmon; however, piscine reovirus (PRV) was identified via RT-rPCR in all 10 affected fish sampled. By histopathology, Jaundice Syndrome is an acute to peracute systemic disease, and the time from first clinical signs to death is likely <48 h; renal tubular epithelial cell necrosis is the most consistent lesion. In an infectivity trial, Chinook Salmon, Sockeye Salmon and Atlantic Salmon, intraperitoneally inoculated with a PRV-positive organ homogenate from jaundiced Chinook Salmon, developed no gross or microscopic evidence of jaundice despite persistence of PRV for the 5-month holding period. The results from this study demonstrate that the Jaundice Syndrome was not transmissible by injection of material from infected fish and that PRV was not the sole aetiological factor for the condition. Additionally, these findings showed the Pacific coast strain of PRV, while transmissible, was of low pathogenicity for Atlantic Salmon, Chinook Salmon and Sockeye Salmon.
Collapse
Affiliation(s)
- K A Garver
- Pacific Biological Station, Fisheries and Oceans Canada, Nanaimo, BC, Canada
| | - G D Marty
- Animal Health Centre, Ministry of Agriculture, Abbotsford, BC, Canada
| | - S N Cockburn
- Pacific Biological Station, Fisheries and Oceans Canada, Nanaimo, BC, Canada
| | - J Richard
- Pacific Biological Station, Fisheries and Oceans Canada, Nanaimo, BC, Canada
| | - L M Hawley
- Pacific Biological Station, Fisheries and Oceans Canada, Nanaimo, BC, Canada
| | - A Müller
- Pacific Biological Station, Fisheries and Oceans Canada, Nanaimo, BC, Canada
| | - R L Thompson
- Western Fisheries Research Center, U.S. Geological Survey, Seattle, WA, USA
| | - M K Purcell
- Western Fisheries Research Center, U.S. Geological Survey, Seattle, WA, USA
| | - S Saksida
- British Columbia Centre for Aquatic Health Sciences, Campbell River, BC, Canada
| |
Collapse
|
21
|
Glitza I, Rohlfs M, Bassett R, John I, Richard J, Iqbal M, Bernzen T, Gerber D, Lacey C, Diab A, Amaria R, Woodman S, Patel S, Yee C, Hwu W, Hwu P, Papadopoulos N, Davies M. 517 Long-term efficacy of intrathecal interleukin-2 (IT IL2) in metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30318-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P. Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunol Res 2015. [PMID: 26216417 DOI: 10.1158/2326-6066.cir-15-0071] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
UNLABELLED Patients with leptomeningeal disease (LMD) from melanoma have very poor outcomes and few treatment options. We present a case of intrathecal (i.t.) administration of autologous tumor-infiltrating lymphocytes (TIL) in a patient with LMD from metastatic melanoma. The patient developed LMD after previous treatments with surgery, high-dose bolus interleukin-2 (HD IL2), and systemic TIL infusion and experienced radiographic progression after intrathecal IL2 (i.t. IL2) therapy. The patient received weekly treatment with increasing numbers of i.t. TIL followed by twice-weekly i.t. IL2. The patient received three i.t. TIL infusions and did not experience any toxicities beyond those expected with i.t. IL2 therapy. Analysis of cerebrospinal fluid demonstrated increased inflammatory cytokines following the i.t. TREATMENTS Subsequent imaging demonstrated disease stabilization, and neurological deficits also remained stable. The patient expired 5 months after the initiation of i.t. TIL therapy with disease progression in the brain, liver, lung, and peritoneal and retroperitoneal lymph nodes, but without LMD progression. These results demonstrate the safety of i.t. administration of TIL in melanoma patients with LMD and support the feasibility of conducting a prospective clinical trial to determine this therapy's clinical benefit among these patients.
Collapse
Affiliation(s)
- Isabella C Glitza
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
| | - Cara Haymaker
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Chantale Bernatchez
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Luis Vence
- Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Michelle Rohlfs
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jessie Richard
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Carol Lacey
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Rahmatu Mansaray
- Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Orenthial J Fulbright
- Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Renjith Ramachandran
- Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Christopher Toth
- Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Seth Wardell
- Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sapna P Patel
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Scott E Woodman
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Wen-Jen Hwu
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Laszlo G Radvanyi
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Michael A Davies
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Nicholas E Papadopoulos
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Patrick Hwu
- Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
23
|
Müller K, Richard J, Volchkov VV, Denechaud V, Bouyer P, Aspect A, Josse V. Suppression and Revival of Weak Localization through Control of Time-Reversal Symmetry. Phys Rev Lett 2015; 114:205301. [PMID: 26047238 DOI: 10.1103/physrevlett.114.205301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2014] [Indexed: 06/04/2023]
Abstract
We report on the observation of suppression and revival of coherent backscattering of ultracold atoms launched in an optical disorder in a quasi-2D geometry and submitted to a short dephasing pulse, as proposed by Micklitz, Müller, and Altland [Phys. Rev. B 91, 064203 (2015)]. This observation demonstrates a novel and general method to study weak localization by manipulating time reversal symmetry in disordered systems. In future experiments, this scheme could be extended to investigate higher order localization processes at the heart of Anderson (strong) localization.
Collapse
Affiliation(s)
- K Müller
- Laboratoire Charles Fabry UMR 8501, Institut d'Optique, CNRS, Univ Paris Sud 11, 2 Avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| | - J Richard
- Laboratoire Charles Fabry UMR 8501, Institut d'Optique, CNRS, Univ Paris Sud 11, 2 Avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| | - V V Volchkov
- Laboratoire Charles Fabry UMR 8501, Institut d'Optique, CNRS, Univ Paris Sud 11, 2 Avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| | - V Denechaud
- Laboratoire Charles Fabry UMR 8501, Institut d'Optique, CNRS, Univ Paris Sud 11, 2 Avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| | - P Bouyer
- LP2N UMR 5298, Univ Bordeaux 1, Institut d'Optique and CNRS, 351 cours de la Libération, 33405 Talence, France
| | - A Aspect
- Laboratoire Charles Fabry UMR 8501, Institut d'Optique, CNRS, Univ Paris Sud 11, 2 Avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| | - V Josse
- Laboratoire Charles Fabry UMR 8501, Institut d'Optique, CNRS, Univ Paris Sud 11, 2 Avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| |
Collapse
|
24
|
Patel SP, Lam S, Rohlfs ML, Fox PS, Richard J, Iqbal M, Bernzen T, Glitza IC, Papadopoulos NE, Hwu P, Davies MA. BRAF and NRAS mutations in Metastatic Melanoma Patients with Leptomeningeal Disease. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e20079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Sruti Lam
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Patricia S Fox
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Jessie Richard
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Masood Iqbal
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Theresa Bernzen
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Patrick Hwu
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
25
|
Liu YQ, Tainoff D, Boukhari M, Richard J, Barski A, Bayle-Guillemaud P, Hadji E, Bourgeois O. Sensitive 3-omega measurements on epitaxial thermoelectric thin films. ACTA ACUST UNITED AC 2014. [DOI: 10.1088/1757-899x/68/1/012005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
26
|
Slattery D, Fox C, Richard J. 80 The Danger of Creating an Oxygen-Enriched Environment in the Back of an Ambulance: The Risk of Various Oxygen-Delivery Devices. Ann Emerg Med 2014. [DOI: 10.1016/j.annemergmed.2014.07.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Rohlfs M, Richard J, Dett T, Gonzalez N, Lacey C, Gerber D, Fox P, Papadopoulos N, Patel S. Mutation Analysis of Melanoma Patients with Leptomeningeal Disease (Lmd) Receiving Intrathecal Interleukin-2 (It-Il-2) at Md Anderson Cancer Center (Mdacc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Prakashkumar MD, Ebenezer M, Richard J. Measurement of Change in the Knowledge and Attitude about Leprosy in Physiotherapy Students Undergoing Intensive One Week Training in Leprosy. Indian J Lepr 2014; 86:99-104. [PMID: 26118221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Leprosy is a disease that causes not only physical problems, but also mental and social problems. In the post integration era, every health care professional needs to understand about leprosy, to be able to diagnose and treat them. Physiotherapy students, in their usual syllabus, have minimal exposure to leprosy, in spite of the fact that they have a major role in preventing impairments and disabilities caused by leprosy, as well as treating such impairments. In order to educate physiotherapy students on leprosy, a one-week intensive training course was organised. This study was done to assess if the intensive training to physiotherapy students resulted in increase in their knowledge on leprosy and change their attitude positively. A batch consisting of 42 physiotherapy students went through the one-week training programme. The improvement in knowledge and attitude were assessed through a pre-test and a post-test design. Results showed that there was significant improvement in knowledge (53.05%) and brought positive change in attitude (75.0%). Such training programmes are recommended for all physiotherapy students.
Collapse
|
29
|
Watson AMM, Prasad KM, Klei L, Wood JA, Yolken RH, Gur RC, Bradford LD, Calkins ME, Richard J, Edwards N, Savage RM, Allen TB, Kwentus J, McEvoy JP, Santos AB, Wiener HW, Go RCP, Perry RT, Nasrallah HA, Gur RE, Devlin B, Nimgaonkar VL. Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol Med 2013; 43:1023-1031. [PMID: 22975221 DOI: 10.1017/s003329171200195x] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Herpes virus infections can cause cognitive impairment during and after acute encephalitis. Although chronic, latent/persistent infection is considered to be relatively benign, some studies have documented cognitive impairment in exposed persons that is untraceable to encephalitis. These studies were conducted among schizophrenia (SZ) patients or older community dwellers, among whom it is difficult to control for the effects of co-morbid illness and medications. To determine whether the associations can be generalized to other groups, we examined a large sample of younger control individuals, SZ patients and their non-psychotic relatives (n=1852). Method Using multivariate models, cognitive performance was evaluated in relation to exposures to herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and cytomegalovirus (CMV), controlling for familial and diagnostic status and sociodemographic variables, including occupation and educational status. Composite cognitive measures were derived from nine cognitive domains using principal components of heritability (PCH). Exposure was indexed by antibodies to viral antigens. RESULTS PCH1, the most heritable component of cognitive performance, declines with exposure to CMV or HSV-1 regardless of case/relative/control group status (p = 1.09 × 10-5 and 0.01 respectively), with stronger association with exposure to multiple herpes viruses (β = -0.25, p = 7.28 × 10-10). There were no significant interactions between exposure and group status. CONCLUSIONS Latent/persistent herpes virus infections can be associated with cognitive impairments regardless of other health status.
Collapse
Affiliation(s)
- A M M Watson
- Departments of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Bruynooghe C, Röwekamp M, Hostikka S, Richard J, Maillet E, Neugebauer W, Zdeněk T. Pertinence of tests used for conformity assessments of fire resistance of nuclear power plant components – opinion of several institutions in Europe. KERNTECHNIK 2013. [DOI: 10.3139/124.110088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract
Fire resistance of structures, systems and components (SSC) is widely identified as a fundamental issue for fire risk assessment at nuclear power plants (NPP). It is currently supported by several national or international ambitious experimental programs. Fire risk assessment at NPPs is performed under a series of hypothesis, e.g. the fire load. A problem will arise if tests used for conformity assessment do not appropriately represent the hypothesis selected during the fire risk analysis. In this case, SSCs may possibly be not meeting the expectations related to their fire resistance capacity supposed by the fire risk analysis. Ways of tackling this issue involve a regulatory approach and adapted requirements for components. While the widespread regulatory approach consists in seeking enveloping scenarios and conservative assumptions, a better knowledge of SSCs behaviour under for NPPs typical situations may be also desirable. The Institute for Energy of the European Commission's Joint Research Centre (JRC) at Petten (NL) launched a questionnaire with the aim of gathering opinions of regulatory bodies and their technical support organisations and manufacturers in Europe on this topic. Major goal was to estimate the relevance of the issue according to the perception of the specialists. The present paper collects the answers given by seven entities (AREVA, GRS, iBMB, IRSN, SJUB, SUEZ-TRACTEBEL, and VTT) and makes suggestions for addressing the issues identified by the participants.
Collapse
Affiliation(s)
- C. Bruynooghe
- European Commission, DG-JRC, Institute for Energy – Nuclear Operation Safety, Westerduinweg 3, 1755 LE Petten, The Netherlands. E-mail:
| | - M. Röwekamp
- GRS mbH, Schwertnergasse 1, 50667 Köln, Germany
| | - S. Hostikka
- VTT Technical Research Centre of Finland, P.O. Box 1000, FI-02044 VTT, Finland
| | - J. Richard
- IRSN, 31, avenue de la Division Leclerc – 92260 Fontenay-aux-Roses, France
| | - E. Maillet
- SUEZ-TRACTEBEL Engineering (GDF SUEZ), Avenue Ariane 7 – 1200 Brussels – Belgium
| | - W. Neugebauer
- AREVA NP GmbH, Freyeslebenstr. 1, 91058 Erlangen, Germany
| | - T. Zdeněk
- State Office for Nuclear Safety (SÚJB), Senovážné náměstí 9, 11000 Prague 1, Czech Republic
| |
Collapse
|
31
|
|
32
|
Thomas M, Ponnaiya J, Emmanuel M, Richard J. Type I reaction in leprosy--a histopathological analysis. Indian J Lepr 2013; 85:1-4. [PMID: 24046908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Even though type 1 lepra reaction (TIR) is a commonly encountered clinical problem, its histology has not yet been clearly delineated. This study attempts to enumerate the most sensitive parameters for the histological diagnosis of TIR. Case records between March 2007 and September 2007 of patients with TIR were reviewed and the biopsies were evaluated by a pathologist blinded to the previous diagnoses. Twenty three patients were included in the study. The most sensitive parameters in our study were dermal edema, intra-granuloma edema and giant cell size. Though clinical findings should remain the mainstay of diagnosis of TIR, the above mentioned parameters should be evaluated in biopsies of leprosy to look for signs of reaction which might otherwise be missed.
Collapse
Affiliation(s)
- M Thomas
- Department of Dermatology, Scheffelin Institute of Health Research and Leprosy Center, Karigiri, Vellore, Tamil Nadu, India.
| | | | | | | |
Collapse
|
33
|
vom Eyser C, Börgers A, Richard J, Dopp E, Janzen N, Bester K, Tuerk J. Chemical and toxicological evaluation of transformation products during advanced oxidation processes. Water Sci Technol 2013; 68:1976-1983. [PMID: 24225097 DOI: 10.2166/wst.2013.452] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The entry of pharmaceuticals into the water cycle from sewage treatment plants is of growing concern because environmental effects are evident at trace levels. Ozonation, UV- and UV/H(2)O(2)-treatment were tested as an additional step in waste water treatment because they have been proven to be effective in eliminating aqueous organic contaminants. The pharmaceuticals carbamazepine, ciprofloxacin, diclofenac, metoprolol and sulfamethoxazole as well as the personal care products galaxolide and tonalide were investigated in terms of degradation efficiency and by-product formation in consideration of toxic effects. The substances were largely removed from treatment plant effluent by ozonation, UV- and UV/H(2)O(2)-treatment. Transformation products were detected in all tested treatment processes. Accompanying analysis showed no genotoxic, cytotoxic or estrogenic potential for the investigated compounds after oxidative treatment of real waste waters. The results indicate that by-product formation from ozonation and advanced oxidation processes does not have any negative environmental impact.
Collapse
Affiliation(s)
- C vom Eyser
- Institut für Energie und Umwelttechnik e. V., IUTA (Institute of Energy and Environmental Technology), Bliersheimer Str. 58-60, 47229 Duisburg, Germany E-mail:
| | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
The thermodynamic treatment of the glass transition remains an issue of intense debate. When associated with the formalism of non-equilibrium thermodynamics, the lattice-hole theory of liquids can provide new insight in this direction, as has been shown by Schmelzer and Gutzow [J. Chem. Phys. 125, 184511 (2006)], by Möller et al. [J. Chem. Phys. 125, 094505 (2006)], and more recently by Tropin et al. [J. Non-Cryst. Solids 357, 1291 (2011); ibid. 357, 1303 (2011)]. Here, we employ a similar approach. We include pressure as an additional variable, in order to account for the freezing-in of structural degrees of freedom upon pressure increase. Second, we demonstrate that important terms concerning first order derivatives of the affinity-driving-force with respect to temperature and pressure have been previously neglected. We show that these are of crucial importance in the approach. Macroscopic non-equilibrium thermodynamics is used to enlighten these contributions in the derivation of C(p),κ(T), and α(p). The coefficients are calculated as a function of pressure and temperature following different theoretical protocols, revealing classical aspects of vitrification and structural recovery processes. Finally, we demonstrate that a simple minimalist model such as the lattice-hole theory of liquids, when being associated with rigorous use of macroscopic non-equilibrium thermodynamics, is able to account for the primary features of the glass transition phenomenology. Notwithstanding its simplicity and its limits, this approach can be used as a very pedagogical tool to provide a physical understanding on the underlying thermodynamics which governs the glass transition process.
Collapse
Affiliation(s)
- J-L Garden
- Institut Néel, CNRS et UJF, 25 Avenue des Martyrs, 38042 Grenoble Cedex 09, France.
| | | | | | | |
Collapse
|
35
|
Jendrzejewski F, Müller K, Richard J, Date A, Plisson T, Bouyer P, Aspect A, Josse V. Coherent backscattering of ultracold atoms. Phys Rev Lett 2012; 109:195302. [PMID: 23215395 DOI: 10.1103/physrevlett.109.195302] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/19/2012] [Indexed: 06/01/2023]
Abstract
We report on the direct observation of coherent backscattering (CBS) of ultracold atoms in a quasi-two-dimensional configuration. Launching atoms with a well-defined momentum in a laser speckle disordered potential, we follow the progressive build up of the momentum scattering pattern, consisting of a ring associated with multiple elastic scattering, and the CBS peak in the backward direction. Monitoring the depletion of the initial momentum component and the formation of the angular ring profile allows us to determine microscopic transport quantities. We also study the time evolution of the CBS peak and find it in fair agreement with predictions, at long times as well as at short times. The observation of CBS can be considered a direct signature of coherence in quantum transport of particles in disordered media. It is responsible for the so called weak localization phenomenon, which is the precursor of Anderson localization.
Collapse
Affiliation(s)
- F Jendrzejewski
- Laboratoire Charles Fabry UMR 8501, Institut d'Optique, CNRS, Univ Paris Sud 11, 2 Avenue Augustin Fresnel, 91127 Palaiseau cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Samuel P, Bushanam JDRS, Ebenezer M, Richard J. Impact of migration on new case detection rates in leprosy in Gudiyatham Taluk, Tamil Nadu, India. Indian J Lepr 2012; 84:307-316. [PMID: 23720895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Migration of persons affected by leprosy was hinted at as early as 1929 (Bhaskara Rao 1930). All new cases of leprosy in Isfahan Province (Iran) were found to be migrants (Asilian et al 2005). Chudasama (2007) suspected increase in leprosy cases in Surat district to migration. These suggest migration contributes to new cases. This study was done to find out 1. Extent of migration among new cases, 2. Characteristics of migrants, 3. Occupational pattern 4.Reasons for migration. 5. Place of origin of migrants 6. Assimilation of migrants into the society. Trained staff collected information regarding migration using special questionnaire from all 222 new untreated cases from the field area of Community Health department during 2004 to 2008. Migrants were 10.4%. Distribution of place of residence, age, gender, marital status, education, mode of detection, Ridley-Jopling and MB/PB classifications of migrants were not significantly different from that of nonmigrants. Grade 2 deformities were more among migrants. All migrants found occupation. Mostly men migrated for job and women for joining their husbands. The role of migration in increasing the number of new cases cannot be minimized. Enhanced efforts should be made to provide adequate medical, health and rehabilitation services for them also.
Collapse
Affiliation(s)
- P Samuel
- Department of Community Health, Schieffelin Institute of Health-Research and Leprosy Centre, Karigiri-632106
| | | | | | | |
Collapse
|
37
|
Artigaud S, Richard J, Flye Sainte-Marie J, Lavaud R, Jean F, Pichereau V. Proteomic responses to heat and hypoxia stresses in a non-model marine species: the King Scallop (Pecten maximus). Comp Biochem Physiol A Mol Integr Physiol 2012. [DOI: 10.1016/j.cbpa.2012.05.194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Sikora A, Ftouni H, Richard J, Hébert C, Eon D, Omnès F, Bourgeois O. Highly sensitive thermal conductivity measurements of suspended membranes (SiN and diamond) using a 3ω-Völklein method. Rev Sci Instrum 2012; 83:054902. [PMID: 22667639 DOI: 10.1063/1.4704086] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
A suspended system for measuring the thermal properties of membranes is presented. The sensitive thermal measurement is based on the 3ω dynamic method coupled to a Völklein geometry. The device obtained using micro-machining processes allows the measurement of the in-plane thermal conductivity of a membrane with a sensitivity of less than 10 nW/K (+∕-5 × 10(-3) Wm(-1) K(-1) at room temperature) and a very high resolution (ΔK/K = 10(-3)). A transducer (heater/thermometer) centered on the membrane is used to create an oscillation of the heat flux and to measure the temperature oscillation at the third harmonic using a Wheatstone bridge set-up. Power as low as 0.1 nW has been measured at room temperature. The method has been applied to measure thermal properties of low stress silicon nitride and polycrystalline diamond membranes with thickness ranging from 100 nm to 400 nm. The thermal conductivity measured on the polycrystalline diamond membrane support a significant grain size effect on the thermal transport.
Collapse
Affiliation(s)
- A Sikora
- Institut NÉEL, CNRS-UJF, 25 avenue des Martyrs, 38042 Grenoble Cedex 9, France
| | | | | | | | | | | | | |
Collapse
|
39
|
Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2011; 118:4014-23. [PMID: 22180178 DOI: 10.1002/cncr.26724] [Citation(s) in RCA: 508] [Impact Index Per Article: 39.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2011] [Revised: 10/19/2011] [Accepted: 10/21/2011] [Indexed: 11/10/2022]
Abstract
BACKGROUND There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) mutations in patients with metastatic melanoma. METHODS Clinical and pathologic data were collected retrospectively on melanoma patients who were clinically tested for BRAF (exon 15) and NRAS (exons 1 and 2) mutations at The University of Texas M. D. Anderson Cancer Center. Analyses were performed to identify significant associations of mutations with tumor and patient characteristics and with survival from the diagnosis of stage IV disease. RESULTS The genotypes of the full cohort (n = 677) were 47% BRAF mutation, 20% NRAS mutation, and 32% wild-type for BRAF and NRAS ("WT"). Tumor mutation status was associated (P = .008) with the risk of central nervous system involvement at the diagnosis of stage IV disease, with a higher prevalence observed in BRAF-mutant (24%) and NRAS-mutant (23%) patients than in WT patients (12%). Among patients with nonuveal melanoma who underwent mutation testing within 6 months of stage IV diagnosis (n = 313), patients with NRAS mutations had a median survival of 8.2 months from stage IV diagnosis, which was shorter than the median survival of WT patients (15.1 months; P = .004). Multivariate analysis of this population incorporating age, sex, metastases (M1) category, serum lactate dehydrogenase level, and mutation status confirmed that NRAS mutations are associated independently with decreased overall survival (vs WT; P = .005; hazard ratio, 2.05). CONCLUSIONS Patients with BRAF or NRAS mutations were more likely than WT patients to have central nervous system involvement at the time they were diagnosed with distant metastatic disease. NRAS mutation status was identified as an independent predictor of shorter survival after a diagnosis of stage IV melanoma.
Collapse
Affiliation(s)
- John A Jakob
- Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Jakob JA, Bassett RL, Ng CS, Lazar AJF, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Davies MA. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8500] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Rajkumar E, Julious S, Salome A, Jennifer G, John AS, Kannan L, Richard J. Effects of environment and education on knowledge and attitude of nursing students towards leprosy. Indian J Lepr 2011; 83:37-43. [PMID: 21638982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The objective of this cross-sectional comparative study was to find the effects of environment and education on knowledge and attitude of nursing students towards leprosy. Data were collected, using a pretested questionnaire, from the first year and third year students of a School of Nursing attached to a leprosy specialty hospital and also from a comparable School of Nursing attached to a general hospital. The results showed that trainees acquired more knowledge on leprosy during training in both schools of nursing. However, those trained in leprosy hospital environment had higher knowledge and attitude scores than those trained in general hospital environment. The attitude of the trainees attached to leprosy hospital was favourable even before they had formal training in leprosy. Those trained in the general hospital showed more favourable attitude after training compared to before training. School of Nursing attached to leprosy hospital provided an atmosphere conducive to learning and understanding more about leprosy. The trainees retained what was learnt because of regular association with patients affected by leprosy. For employment in hospital or community based services or research related to leprosy, nurses trained in a leprosy hospital would have added value of knowledge and attitude.
Collapse
Affiliation(s)
- E Rajkumar
- Karigiri School of Nursing, Schieffelin Institute of Health-Research and Leprosy Centre, Karigiri-632106, Tamil Nadu, India
| | | | | | | | | | | | | |
Collapse
|
42
|
Dos Santos IR, Thies C, Richard J, Le Meurlay D, Gajan V, Vandevelde V, Benoit JP. A supercritical fluid-based coating technology. 2: Solubility considerations. J Microencapsul 2010. [DOI: 10.3109/02652040309178052] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
43
|
Dos Santos IR, Richard J, Thies C, Pech B, Benoit JP. A supercritical fluid-based coating technology. 3: Preparation and characterization of bovine serum albumin particles coated with lipids. J Microencapsul 2010. [DOI: 10.3109/02652040309178053] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
44
|
Thies C, Dos Santos IR, Richard J, Vandevelde V, Rolland H, Benoit JP. A supercritical fluid-based coating technology 1: Process considerations. J Microencapsul 2010. [DOI: 10.3109/02652040309178051] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
45
|
Richard J, Bushanam RS, Samuel P, Ebenezer M. Recent trends in new case detection rates in leprosy by age and sex in Gudiyatham Taluk, Tamil Nadu, India. Indian J Lepr 2010; 82:131-135. [PMID: 21449224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
In the race towards eradication of leprosy, the emphasis has shifted from prevalence to new case detection rates which are proxyfor true incidence rates. There is great need for reliable data on new case detection rates over time, classified by age and sex. In this paper, the trend of age specific and sex specific new cases detection rates, from 2001 to 2009, for the field area of Schieffelin Institute of Health-Research and Leprosy Centre are presented and implications discussed. The appropriate age distribution of Census of India 2001 was used to estimate the age distribution of the area. Three year moving averages were computed for age specific rates. The age group 55+ had the highest rate among all age groups from 2002 to 2006 and afterwards declined a little. The rates of ages 15-34 and 35-54 were high and their patterns over 2002 to 2008 were the same. The specific rates of children (0-14) were declining generally through 2002 to 2008. The specific rates of males were slightly higher than the females all through 2001 to 2009 but the difference between male and female rates was not significant at anyyear (P > 0.05).
Collapse
Affiliation(s)
- J Richard
- Schieffelin Institute of Health-Research and Leprosy Centre, Karigiri-632 106, Tamil Nadu, India.
| | | | | | | |
Collapse
|
46
|
Sathiaraj Y, Norman G, Richard J. Long term sustainability and efficacy of self-care education on knowledge and practice of wound prevention and management among leprosy patients. Indian J Lepr 2010; 82:79-83. [PMID: 21434510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
In a chronic disease like leprosy, assessment of self-care education of long duration is necessary to find out its effectiveness and to bring out sustainability both in the point of view of the provider and of the recipient. Self-care education was imparted to patients for 8 years in the Katpadi Block as part of 'prevention of impairment and disability' programme from the year 2000 onwards. The patients were provided with knowledge regarding 'inspection' for pre-disposing factors of wound development and about external causes (trauma) or dangerous environments for wound development. Additionally, they were given practice on self-care techniques for prevention and management of wounds. Staff as part of their routine work has been doing this. An evaluation, done by independent assessor, compared the effect of this programme with a control area where no such programme was going on. This showed that the self-care education resulted in very high level of knowledge and practice compared to the control area, even up to 100% practice in some aspects. Self-care education is effective, can be sustained for a long time and also can be carried out as part of routine work.
Collapse
Affiliation(s)
- Y Sathiaraj
- Department of Community Health, Schieffelin Institute of Health-Research and Leprosy Centre, Karigiri-632106, Tamil Nadu, India.
| | | | | |
Collapse
|
47
|
Swinbank AM, Smail I, Longmore S, Harris AI, Baker AJ, De Breuck C, Richard J, Edge AC, Ivison RJ, Blundell R, Coppin KEK, Cox P, Gurwell M, Hainline LJ, Krips M, Lundgren A, Neri R, Siana B, Siringo G, Stark DP, Wilner D, Younger JD. Intense star formation within resolved compact regions in a galaxy at z = 2.3. Nature 2010; 464:733-6. [PMID: 20305639 DOI: 10.1038/nature08880] [Citation(s) in RCA: 274] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2009] [Accepted: 02/01/2010] [Indexed: 11/09/2022]
|
48
|
Ducel V, Pouliquen D, Richard J, Boury F. 1H NMR relaxation studies of protein-polysaccharide mixtures. Int J Biol Macromol 2008; 43:359-66. [PMID: 18687356 DOI: 10.1016/j.ijbiomac.2008.07.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Revised: 07/09/2008] [Accepted: 07/10/2008] [Indexed: 11/20/2022]
Abstract
NMR water proton relaxation was used to characterize the structure of plant proteins and plant protein-polysaccharide mixtures in aqueous solutions. The method is based on the mobility determination of the water molecules in the biopolymer environment in solutions through relaxation time measurements. Differences of conformation between pea globulin and alpha gliadin seem to control the water molecules mobility in their environment. As deduced from the study of complexes, the electrostatic interactions may also play a major role in the water molecule motions. The phase separation induced under specific conditions seems to promote the translational diffusion of structured water molecules whereas the rotational motion was more restricted.
Collapse
Affiliation(s)
- V Ducel
- INSERM unité 646, Ingénierie de la Vectorisation Particulaire, 10 rue A. Boquel, 49100 Angers, France
| | | | | | | |
Collapse
|
49
|
Garden JL, Richard J, Guillou H. Erratum: “Temperature of systems out of thermodynamic equilibrium” [J. Chem. Phys. 129, 044508 (2008)]. J Chem Phys 2008. [DOI: 10.1063/1.2982513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Abstract
Two phenomenological approaches are currently used in the study of the vitreous state. One is based on the concept of fictive temperature introduced by Tool [J. Res. Natl. Bur. Stand. 34, 199 (1945)] and recently revisited by Nieuwenhuizen [Phys. Rev. Lett. 80, 5580 (1998)]. The other is based on the thermodynamics of irreversible processes initiated by De Donder at the beginning of the last century [L'Affinite (Gauthier-Villars, Paris, 1927)] and recently used by Moller et al. for a thorough study of the glass transition [J. Chem. Phys. 125, 094505 (2006)]. This latter approach leads to the possibility of describing the glass transition by means of the freezing-in of one or more order parameters connected to the internal structural degrees of freedom involved in the vitrification process. In this paper, the equivalence of the two preceding approaches is demonstrated, not only for glasses but in a very general way for any system undergoing an irreversible transformation. This equivalence allows the definition of an effective temperature for all systems departed from equilibrium generating a positive amount of entropy. In fact, the initial fictive temperature concept of Tool leads to the generalization of the notion of temperature for systems out of thermodynamic equilibrium, for which glasses are just particular cases.
Collapse
Affiliation(s)
- J-L Garden
- Institut Néel, CNRS et Université Joseph Fourier, BP 166, 38042 Grenoble Cedex 9, France.
| | | | | |
Collapse
|